PSY30 Biologic Treatments for Moderate to Severe Naïve Psoriatic Patients: A Budget Impact Analysis In Italy  by Povero, M & Pradelli, L
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A663
in treatment and prophylaxis of patients with von Willebrand disease is approved 
from a pharmacoeconomic point of view.
PSY28
Budget ImPact analYSIS of daSatYnIB In treatment of adult 
PatIentS WIth PhIladelPhIa chromoSome PoSItIve (Ph+) acute 
lYmBPhoBlaStIc leukemIa (all) WIth reSIStance or Intolerance to 
PrIor theraPY In Poland
Mucha J1, Stelmachowski J1, Walczak J1, Pieniazek I1, Labak-Klimasara M2, Obrzut G1
1Arcana Institute Ltd, Krakow, Poland, 2Bristol-Myers Squibb Services Sp. z o.o., Warsaw, Poland
Objectives: The purpose was to estimate the financial consequences of reimburse-
ment of dasatinib in adult population with Ph+ ALL with resistance or intolerance 
to prior therapy in Poland. MethOds: The budget impact model was developed 
to evaluate the consequence for National Health Fund budget in Poland in case 
of reimbursement of dasatinib. Two scenarios were considered: with and with-
out dasatinib reimbursement in two-years’ time horizon (2015-2016). In scenario 
with reimbursement, dasatinib would be used instead the FLAM chemotherapy 
(fludarabine, cytarabine, mitoxantrone). Based on the Polish epidemiological data 
the target population – adult patients Ph+ ALL with resistance or intolerance to 
prior therapy – was estimated at 12 patients in one year (with range from 5 to 24). 
Direct medical costs: substances and their administration (assessed chemothera-
pies), monitoring, allogeneic hematopoietic stem cell transplantation (allo-HSCT), 
monitoring after allo-HSCT and palliative care were considered. All calculations 
were performed with the Excel model constructed for economic evaluation and 
budget impact assessment. Results: If the reimbursement of dasatinib is intro-
duced, the annual expenses from the budget of National Health Fund in Poland 
would increase by € 127,279 in the first year and € 189,224 in the second year of reim-
bursement. However, change from FLAM to dasatinib will decrease the necessity and 
length of hospitalization due to the different administration route. cOnclusiOns: 
Reimbursement of dasatinib in Poland will bring additional costs incurred by public 
payer, however, it will also increase the survival of patients with ultra-rare disease 
which is ALL and consequently improve their quality of life.
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Budget ImPact analYSIS of canacInumaB In the treatment of 
PatIentS WIth muckle–WellS SYndrome In the ruSSIan federatIon
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Objectives: To conduct budget impact analysis (BIA) of canakinumab treatment 
group comparing to symptomatic treatment in retrospective group of patients suf-
fering from Muckle–Wells Syndrome (MWS). MethOds: BIA was conducted of the 
canakinumab treatment group versus retrospective group with only symptomatic 
treatment. According to the expert opinion canakinumab treatment accompanied by 
vial sharing and it has been taken into consideration of drug cost therapy. Following 
direct medical costs were also included into analysis and based on expert opinion: 
administration costs, costs of diagnostic laboratory and instrumental procedure, costs 
of inpatient and outpatient visits, costs of treating MWS complications and costs for 
correction adverse events. One-year time horizon was used. Results: Cost of canaki-
numab therapy course was 40,830,937 RUB/ 668,220 EUR for 20 MWS patients within 
1 year. The difference in the required budget funds between canakinumab treatment 
group and retrospective group with symptomatic treatment was 38,787,076 RUB/ 
634,771 EUR for 20 patients within 1 year. Decrease of direct medical costs (excluding 
costs for drug therapy) was obtained in canakinumab treatment group and amounted 
763,705 RUB/ 12,498 EUR for 20 patients within 1 year due to a lower frequency of 
inpatient and outpatient visits, complications of MWS and lower administration costs 
in group treated with canakinumab. cOnclusiOns: Usage of canakinumab in the 
treatment of patients with MWS led to budget spending. However, good efficacy of 
canakinumab helped to reduce direct medical costs for 763,705 RUB/12,498 EUR for 
20 patients within 1 year in canakinumab treatment group.
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Objectives: Evaluate the current prescription trend in Italy and estimate the 
impact of alternative market hypothesis including the introduction of inflixi-
mab biosimilars. MethOds: Biologics currently indicated for psoriasis include 
tumor necrosis factor (TNF)-α inhibitors adalimumab, etanercept, and infliximab, 
as well as the interleukin-12/23 inhibitor ustekinumab. A deterministic Markov 
model was developed to simulate the evolution of bio-naïve psoriatic patients 
in Italy for 3 years. Event rates (mortality, malignancies, infections and MACEs) 
and persistence curves, were modeled for each biologic drug used in first, second 
and third line, basing on published data. Hospitalization costs were calculated 
as average of Italian DRGs weighted for event-related frequency. The cost of a 
dermatological visit was considered every two months and in case of therapy 
switch. All costs were calculated from the perspective of NHS. The current Italian 
market mix of biologic treatments was compared with the total substitution of 
infliximab with its biosimilars combined with ustekinumab increasing its mar-
ket share to 40% at the expenses of the remaining biologics, proportionally to 
their current shares. Results: In the next three years, 515 bionaive patients are 
expected to start a new biological treatment annually. Total cost results in about 
45.7 million Euro for 3 years in the current scenario corresponding to 15,148 Euro/
patient yearly. Increasing in ustekinumab market shares and the introduction of 
infliximab biosimilars lead to estimated annual savings of about 670 Euro/patient 
(1.7 million Euro in 3 years). Cost of biologic therapy is the main driver, while der-
matological visits and adverse events management represent less than 1% of the 
total cost. cOnclusiOns: Biological treatment cost of psoriasis depends almost 
completely from pharmacological therapy. Changes in the current prescription 
validation. Further research about the value and accuracy of existing instruments 
in clinical practice is required.
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modellIng the lIkelY ImPact of the oBeSItY ePIdemIc on mortalItY 
and cauSe of death In older adultS
Martin A, Martin C
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Objectives: The UK population is ageing, and the prevalence of obesity is increas-
ing. To assess the likely impact of these two demographic trends, we used a sto-
chastic all-cause, cause of death mortality model to determine changes in likely 
age of death associated with different body mass index (BMI) values in older 
adults. MethOds: The Sonata Vivo model adjusts population baseline mortality 
for known risk factors to calculate the mean age of death and most likely causes 
of death for an individual, and has been validated against long-term cohorts in the 
UK and USA. We used the model to calculate the difference in mean ages of death 
at BMIs of 27, 33, 37 and 42 compared with a BMI of 22 in men and women aged 55 
to 90. We assumed all subjects were non-smokers with population average values 
for blood pressure, cholesterol and alcohol consumption. Results: In adults aged 
55 years at baseline, increasing BMI from 22 to 42 was associated with a decrease 
in mean age of death of 1.93 years in women and 1.89 years in men. The absolute 
difference in life expectancy across the BMI range decreased with increasing age 
at baseline, to 0.34 years in women and 0.15 years in men aged 90. As expected, 
the model predicts a longer life expectancy in women than men at each age and 
BMI, but the relative difference between genders was smaller in those with a BMI 
of 42 than in those with a BMI of 22. Analysis by likely cause of death in 55 year old 
adults showed the main impact of obesity was on cardiovascular (CVD) and cancer 
deaths in women, and CVD and endocrine deaths in men. cOnclusiOns: Obesity 
is likely to reduce life expectancy by up to 2 years in older adults in the UK, mainly 
from increased CVD mortality.
SYStemIc dISorderS/condItIonS – cost Studies
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Objectives: The aim of this study was to evaluate the Budget Impact (BI) of 
treatment of Crohn’s disease with adalimumab (ADA) from the perspective of the 
Brazilian Private Health Care System (BPHCS) over a 5 year time period. MethOds: 
An epidemiological model based on the Private Health Care System population, 
DataSUS database and published literature was developed to estimate eligible 
patients in the next five years. The BI was simulated comparing the current sce-
nario (patients treated with intravenous infliximab [IFX]) with a new scenario 
(the introduction of ADA for Crohn’s disease treatment), BPHCS perspective. The 
market-share for ADA starts at 20% during the first year and rises to 80%. Dose per 
application, number of vial/syringe, cost of application and median of weight were 
based on scientific literature. The drug prices were based on Factory Prices plus 
18% taxes from CMED. A deterministic sensitivity analysis (DSA) was performed 
to determinate the impacts in results. Results: 10,035 patients were eligible 
for treatment with either IFX or ADA over the five years of analysis. In the base 
case scenario, the Budget Impact simulation presented a decrease of total cost 
by R$1,942,434.38 in the first year and reached a decrease of R$9,089,493.93 in the 
fifth year. The cumulative economic savings for the five years in the simulation 
with ADA introduction was R$26,879,457.87. In deterministic sensitivity analysis 
cost per vial of IFX, cost per syringe of ADA and market-share of patients were the 
most important variables that impacted results. A majority of DSA scenarios indi-
cated that treatment with ADA provides cost savings. cOnclusiOns: The utiliza-
tion of ADA may generate economic savings for the Brazilian Private Health Care 
System that may allow more eligible patients with Crohn’s disease to be treated 
with ADA.
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Budget ImPact analYSIS of Blood clottIng factor concentrateS In 
the treatment of von WIlleBrand dISeaSe
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Objectives: To conduct a budget impact analysis of treatment and prophylaxis 
of acute bleedings among patients with von Willebrand disease using blood clot-
ting factor concentrates (clotting factor VIII + von Willebrand factor) in the Russian 
Federation. MethOds: Clinical effectiveness assessment was based on the results of 
modeling of the treatment and prophylaxis of patients with von Willebrand disease 
using blood clotting factor concentrates (clotting factor VIII + von Willebrand factor) 
within one year (time horizon). The required data was obtained from literature review 
within PubMed and E-library, and from experts in hematological healthcare centers 
in Russia. Cost analysis included assessment of direct and indirect costs that can 
be associated with analyzed schemes of treatment (“No prophylaxis”, “Prophylaxis 
¹1” – median purity concentrate VWF:RCo/FVIII= 0,5/1, “Prophylaxis ¹2” - high purity 
concentrate VWF:RCo/FVIII= 2,5/1, “Prophylaxis ¹3” - high purity concentrate VWF:RCo/
FVIII= 0,9/1). Cost data was based on median prices for medicines and medical services 
in National healthcare system in the Russian Federation. Results: In case of switch-
ing from regimens: “No prophylaxis”, “Prophylaxis ¹1”, “Prophylaxis ¹2”, to the regular 
preventive administration with the scheme “Prophylaxis ¹3” total costs per all popula-
tion within one year can be reduced by 21906000 rubles ($ 396 360), 22143000 rubles 
($ 400 648) and 5752000 rubles ($ 104 075), respectively. cOnclusiOns: Obtained 
results demonstrates that the use of high purity concentrate VWF:RCo /FVIII= 0,9/1 
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test, Wilcoxon test, Chi-square test) were: number of patients exposed to allogeneic 
red cells, amount of blood transfusions, and the number of length of stay in hospital. 
An economic model was quantified the cost saving of EVICEL® in ICH. Results: 
preliminary results showed that application of EVICEL reduce number of transfused 
RBC, postoperative haemoglobin loss, and days of hospital stay. In the hospital cost. 
analysis EVICEL® predicts resource reduction with average cost-savings of € 1.227 
per patient. cOnclusiOns: Overall, the results suggest that EVICEL are efficacious 
in reducing both post-operative blood loss, and hospital stay The protocol with 
EVICEL® produce clinical appropriateness and important cost savings for hospital.
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SWItchIng from rItuxImaB IntravenouS InjectIon to rItuxImaB 
SuBcutaneouS InjectIon In france
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Objectives: A pilot project concerning the evaluation of potential cost-saving for 
switching from chemotherapy (rituximab) intravenous injection (IV) to chemother-
apy subcutaneous injection (SC) at national level in France” was selected to demon-
strate added benefits beyond clinical effectiveness. MethOds: To define the added 
value of rituximab SC injection improvement a 5-step methodology was defined as 
follow: 1) Define the key value drivers (cost/benefits), 2) Implement decision tree, 
3) Estimate the associated patient flow, 4) Evaluate the direct and indirect costs of 
patient flow including hospital and insurance perspectives, 5) Communication to the 
stakeholders. For rituximab SC injection versus rituximab IV injection the decision 
tree model was developed using the French health care with rituximab marketing 
authorizations. Epidemiologic data were estimated with internal market share data 
and the French health watch institute. Results: Four main benefits emerged at 
national level; (i) A reduction in staff time was observed for nurses, pharmacists and 
technicians leading to a potential saving at 300 000€ per year. (ii) A potential saving 
of 500 000€ per year was observed for the reduction in consumables. (iii) The shorter 
occupancy of chair for SC injection was leaded to a potential saving of 700 000€ 
per year. (iv) Reduction in wastage was 300 000€ per year thanks to sub-cutaneous 
injection. cOnclusiOns: Results showed that cost-saving from switching for IV 
to SC exist. Other potential benefits should be investigated to demonstrate all value 
of medicine product. Therefore, a quality of life study is planned to demonstrate 
potential added value of rituximab SC vs. rituximab IV in France. Cost-effectiveness 
study should be also performed to demonstrate potential cost saving per quality 
adjusted life year.
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Objectives: Alpha-1 antitrypsin deficiency (AATD) is a rare, under-diagnosed disease 
that may predispose an individual to chronic obstructive pulmonary disease (COPD) 
early in life. Affected individuals often undergo long delays between symptomatology 
and diagnosis, and are commonly treated like standard COPD patients before receiv-
ing proper treatment with expensive AAT inhibitors. Recognizing the differences 
between these conditions may speed identification of AATD patients and prevent mis-
diagnosis. This study’s objective was to define differences between individuals with 
AATD and non-AATD associated COPD. MethOds: Patient demographics, emergency 
room (ER) and inpatient visits, and costs (ER, inpatient, outpatient) between AATD and 
COPD patients were assessed using 2011-2013 Medicare data. ER and inpatient visits, 
and costs were assessed during a 1-year post period following confirmed COPD or 
AATD diagnosis. Results: Mean age of COPD (n= 183,832) and AATD (n= 279) cohorts 
were 72.6±11.3 and 64.6±11.7 years, respectively (p< 0.001). Among COPD patients, 
20.3% were receiving disability benefits, which was significantly less than AATD 
patients (40.1%; p< 0.001). COPD mean Charlson Comorbidity Index (CCI) score was 
3.7±2.7, while AATD was 2.4±2.0 (p< 0.001). AATD patients had more ER (58.4%) and 
inpatient (58.0%) visits than COPD patients (42.5% and 19.5%, respectively; p< 0.001). 
Despite the fact that only 13% of AATD patients were receiving AAT inhibitors, AATD 
total healthcare costs (per patient) were still $27,674 greater than COPD total costs 
(p< 0.001). cOnclusiOns: Our results show that even though our AATD Medicare 
patients are younger and have lower CCI scores, they experience more ER and inpa-
tient visits, and cost more to the healthcare system compared to older, less healthy 
COPD patients. Identifying the medical burden of AATD, raises attention to the need 
for an effective screening tool for identifying AATD patients among those who have 
COPD as well as better understanding AATD disease progression.
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economIc ImPact of emPloYment StatuS on the SocIal coSt of 
morBId oBeSe PatIentS SuBmItted to BarIatrIc SurgerY
Bellelli S, Turchetti G
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Objectives: The aim of the longitudinal multicenter study is to estimate the eco-
nomic impact of employment status on the social cost of a patient submitted to 
bariatric surgery techniques. MethOds: Individual socio-economic and clinical 
data have been collected for adult patients in charge to 6 Hospital in Italy at time 
of intervention of gastric banding, gastric by-pass and sleeve gastrectomy and fol-
lowed up to 1 year. Direct medical costs were estimated using tariffs for laboratory 
tests, diagnostic exams, visits, and prices for drugs. Procedure and inpatient cost 
data were collected at Center level. Non medical costs included costs for travel and 
accommodation, domestic help and informal care. The human capital approach 
has been used for estimating the loss of productivity of patients. The incremen-
tal effects of employment status on social cost were estimated by multivariate 
scenario, with adoption of the most persistent biologic (ustekinumab), can lead to 
valuable savings through lower cost of maintenance phase, avoided re-inductions, 
and reduced visits.
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Objectives: Rare diseases such as ulcerative colitis (UC) have significant impact 
on patients and their families, as well as the healthcare systems and societies. 
The high costs of medicines makes actual researches in this field. The main aim 
of this study was to perform budget impact analysis of using combination of bio-
logics - infliximab + golimumab in equal proportions. MethOds: Analysis of the 
published clinical trials was conducted to evaluate comparative efficacy and safety 
of the using of different types of biologics therapies – infliximab, golimumab. To 
measure costs of ulcerative colitis for the state budget were used “cost of illness” 
and “budget impact” analyses. Direct medical costs included diagnosis, treatments, 
medications, blood and its components, nutrient mixture and were calculated for 
1 year-therapy. In this study were performed 2 variants of UC treatment costs, in 
1st variant was used infliximab, in 2nd variant - infliximab + golimumab in equal 
proportions. Results: According to published trials golimumab was provided effi-
cacy similar to infliximab in inducing and maintaining clinical remission, clinical 
response, and mucosal healing. Loss of response was occurred in approximately 
30% of patients, leading to discontinuation of biologic therapy and/or colectomy. 
So using the combination of biologics was preferred. The mean annual overall 
direct health care cost of UC treatment for 1 patient with infliximab was esti-
mated to be 456 000 rubles ($ 8 514), and with infliximab + golimumab in equal 
proportions – 533 256 rubles ($9 957). Thus budget impact of using combination 
of 2 biologics - infliximab + golimumab in equal proportions was estimated to be 
14%. cOnclusiOns: Golimumab was provided efficacy similar to infliximab and 
the use combination of 2 biologics infliximab + golimumab in equal proportions 
for treatment UC has little effect on the budget.
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hemodIalYSIS or PerItoneal dIalYSIS In ruSSIa
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Objectives: to assess the cost effectiveness of the application of darbepoetin alfa 
vs other erythropoiesis-stimulating agents for anemia correction in patients on 
hemodialysis or peritoneal dialysis. MethOds: The pharmacoeconomic model, 
providing the construction of decision tree, under which patients are treated by 
different ESP to achieve various levels of hemoglobin, was designed. To assess of 
the dosing schedule actual practice in the Russian healthcare system was perform 
a retrospective observational study (date from the 11 hospitals of Russia). The 
main method of pharmacoeconomic analysis was “cost-consequence” method 
and the analysis of the “impact on the budget”. A multivariant sensitivity analysis 
of the model relative to the cost of darbepoetin alfa ± 10 %, relative to the dose 
of darbepoetin alfa reduction at a level of 20 % and 47 % (based expert data) and 
relative to changes in hospitalization costs was performed. Results: The data 
on actual practice of darbepoetin alfa dossage in Russia indicate on a possible 
reduction of the dose during treatment an average of 47%. The total economy of 
budget per year (with respect to 1 patient) to hemodialysis patients may reach 
from 223,6 $ (for target hemoglobin values 11 (± 1) g/dL) to 616,47 $ (for hemo-
globin values 9 (± 1) g/dL). The total economy of budget per year for patients on 
peritoneal dialysis may reach from 216,32 $ (for 11 (± 1) g/dL) to 345,41 $ (for 
9 (± 1) g/dl). cOnclusiOns: The darbepoetin alfa application for anemia cor-
rection in patients on hemodialysis or peritoneal dialysis is more cost-effective 
treatment option compared with other alternative erythropoiesis-stimulating 
drugs.
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Objectives: Blood transfusion and hemostasis are becoming an important aspect 
of preoperative planning and intraoperative decision making in orthopaedic sur-
gery. Total hip arthroplasty (THA), place patients at risk of significant blood loss, 
which can result in the need for transfusion, risk of postoperative anemia and 
infection, and increase hospital stay. Humanitas Hospital (ICH) use a new protocol 
“without blood” perioperative strategies include the use of autologous blood dona-
tion and administration of erythropoietin; intraoperative measures include acute 
normovolemic hemodilution, anesthesia, use of tranexamic acid, intraoperative 
and postoperative blood salvage, specialized cautery, and a new topical hemostatic 
agents (EVICEL). Evicel is a fibrin sealant (fibrinogen and high concentration of 
thrombin) hemostatic agent, facilitates hemostasis, reduce the volume of blood 
loss in postoperative. The potential role and cost saving generated from use of 
EVICEL in the “protocol without blood” to control blood loss, number of avoid blood 
transfusions and reduction of length of hospital stay in patients undergoing THA 
revisions. MethOds: was evaluated in a retrospective observational controlled 
study in patients undergoing THA revision: one group was treated with EVICEL and a 
control group with the same protocol but without EVICEL. The outcomes measured (t 
